ACTU earnings analysis
What we found in ACTU's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The extracted 10-Q text does not include income statement, balance sheet, cash flow, segment, or quantitative guidance data, so operating trends and EPS performance cannot be assessed. Management reported effective disclosure controls as of June 30, 2026 and no material internal-control changes during the quarter. The principal material development is the Nasdaq listing deficiency: the company was below the $50 million MVLS requirement and has until January 11, 2027 to regain compliance.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Disclosure controls deemed effective
- Management concluded that disclosure controls and procedures were effective at a reasonable assurance level as of June 30, 2026.
- No material control changes
- The company reported no changes in internal control over financial reporting during the three months ended June 30, 2026 that materially affected, or were reasonably likely to materially affect, those controls.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Nasdaq MVLS deficiency
- The company is not currently compliant with Nasdaq Global Market's $50 million minimum market value of listed securities requirement. Nasdaq notified the company on July 15, 2026 that it had failed the requirement for the 30-business-day period ended July 14, 2026.
- Potential Nasdaq delisting
- The company has until January 11, 2027 to restore compliance by maintaining market value of listed securities at or above $50 million for at least 10 consecutive business days; failure could lead to delisting proceedings.
- Liquidity and capital-raising impact
- If delisted and not accepted for Nasdaq Capital Market listing, the company expects trading could move to an over-the-counter market, and its securities could become subject to SEC penny-stock rules; continued listing also includes a $1.00 minimum bid-price standard.
What they said about what is next.
No quantitative revenue or EPS outlook is provided in the extracted filing text; outlook appears deferred to other company communications.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 14, 2026
- Actuate Therapeutics remains firmly in a pre-revenue stage, reporting no revenue for Q1 2026 once again. The net loss for the quarter was $5.63 million, a slight improvement compared to the $6.32 million loss in Q1…
- 10-K · March 26, 2026
- Actuate Therapeutics reports positive Phase 2 results in first-line metastatic pancreatic cancer (Actuate-1801 Part 3B) showing statistically significant survival benefit versus GnP and plans regulatory discussions in…
- 10-Q · May 15, 2025
- Actuate reported a Q1 2025 net loss of $6,317,024 (loss per share $(0.32)) and used $4,618,740 in operating cash during the quarter. Cash declined to $3,889,405 from $8,641,622 at year-end, management says cash will not…
- 10-Q · September 24, 2024
- Actuate reported no revenue and a larger net loss for Q2 2024: net loss was $(6,572,219) and diluted EPS was $(4.20) versus $(5,524,286) and $(3.88) in Q2 2023. Liquidity was stressed at June 30, 2024 with cash of…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing ACTU makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever